1Malik P,Cashen AF. Decitabine in the treatment of acute myeloid leukemia in elderly patients [ J ]. Cancer Manag Res,2014,6:53 - 61.
2Zagonel V, Lo RG, Marotta G, et al. 5-Aza-2'- deoxycytidine (Decitabine) induces trilineage response in unfavourable myelodysplastic syndromes [ J ]. Leukemia, 1993,7:30 - 35.
3Kantarjian H, Issa JPJ, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes [ J ]. Cancer,2006,106 (8) : 1794 - 1803.
4Ltibbert M, Suciu S, Baila L, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy:final results of the randomized phase m study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group [ J ]. J Clin Oneo1,2011,29 ( 15 ) : 1987 - 1996.
5Kantarjian H, Oki Y, Garcia-Manero G,et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastie syndrome and chronic myelomonocytic leukemia [ J ]. Blood, 2007,109 ( 1 ) : 52 -57.
6Steensma DP, Baer MR, Slack JL, et al. Muhicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastie syndromes:the alternative dosing for outpatient treatment (ADOPT) trial[ J]. J Clin Oncol, 2009,27 ( 23 ) : 3842 - 3848.
7Lee JH,Jang JH,Park J, et al. A prospective muhicenter observational study of deeitabine treatment in Korean patients with myelodysplastic syndrome [ J ]. Haematolo- gica,2011,96(10) :1441 - 1447.
8Garcia-Manero G, Jabbour E, Borthakur G, et al. Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes [ J ]. J Clin Oncol, 2013,31 ( 20 ) : 2548 - 2553.
9Issa JPJ, Garcia-Manero G, Giles FJ,et al. Phase 1 study of low-dose prolonged exposure schedules of the hypo- methylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietie malignancies [ J ]. Blood, 2004, 103 ( 5 ) : 1635 - 1640.
10Saunthararajah Y. Key clinical observations after 5- azacytidine and decitabine treatment of myelodysplastic syndromes suggest practical solutions for better outcomes [J]. ASH Education Program Book,2013,2013 ( 1 ) : 511 -521.
4Myers MP, Stolarov JP, Eng C, et al. PTEN, the tumor suppres- sor from human chromosome 10q23, is adual specificity phospha- tase. Proc Natl Acad Sci U S A, 1997, 94: 9052-9057.
5Jabbour E, Issa JP, Garcia-Manero G, et al. Evolution of decit- abine development : accomplishments, ongoing investigations, andfuture strategies. Cancer, 2008,112:2341-2351.
6Li P,Li C,Zhao X,et al. 1727( KIP1 ) stabilization and G1 arrest by 1,25-dihy- droxyvitamin D (3) in ovarian cancercells mediated through down-regulation of cyclin E/cyc-lin-dependent kinase 2 and Skpl-Cullin-F-box protein /Skp2 ubiqnitin ligase. J Biol Chem ,2004,279 : 25260-25267.
7Martin V, Valencia A, Agirre X, et al. Epigenetic regulation of the non- canonical Wnt path wayin acute myeloid leukemia. Canc- er Science, 2010,101: 425-432.
8Oka T, Ouchida M, Koyama M, et al. Gene silencing of the tyro- sine phosphatase SHP1 gene by aberrant methylation in leukemias/ lymphomas. Cancer Res, 2002,62 : 6390-6394.
9EI-Osta A. The rise and fall of genomic methylation in cancer. Leu- kemia, 2004, 18:233-237.
10Issa JP, Garcia-Manero G, Giles FJ, et al. Phase 1 study of low dose prolonged exposure schedules of the hypomethylating gent 5 aza 2'deoxycytidine (decitabine) in hematopoietic malignancies. Blood, 2004, 103 : 1635-1640.
